Back

Head to head comparison of semaglutide and colchicine for treating atrial remodeling in post-MI rats with reduced ejection fraction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Advances in mechanisms, genetic insights, and therapeutic strategies for atrial fibrillation and atrial remodelling Arrhythmias ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Yoram Etzion

Ben-Gurion University of the Negev, Beer Sheva (Israel)

8 More presentations in this session

Presentation thumbnail
Discussant - Advances in mechanisms, genetic insights, and therapeutic strategies for atrial fibrillation and atrial remodelling
Presentation thumbnail
Disrupted circadian rhythm in sleep disordered breathing promotes atrial fibrillation in human myocardium
Doctor P. Hegner (Regensburg, DE)
Abstract
Presentation thumbnail
Nation-wide GWAS meta-analysis reveals new genetic locus for early-onset atrial fibrillation
Doctor M. Mattingsdal (Gjettum, NO)
Abstract
Presentation thumbnail
The KCNN3 rs13376333 risk variant reduces the SK-current density in isogenic stem cell-derived and native human atrial myocytes
Doctor V. Jimenez Sabado (Barcelona, ES)
Abstract
Presentation thumbnail
Epicardial adipose tissue drives to macrophages response during the atrial cardiomyopathy
Mrs N. Suffee (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Advances in mechanisms, genetic insights, and therapeutic strategies for atrial fibrillation and atrial remodelling

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Semaglutide improves contractile function in isolated human atrium
thumbnail
Congress Presentation
Inflamed atrial tissues of patients with atrial fibrillation are characterized by pro-oxidant and pro-remodeling responses: synergistic inhibition by an SGLT2 inhibitor plus a GLP-1R activation
thumbnail
Congress Presentation
BA6b9, a novel sk4 K + channel blocker, attenuates atrial fibrillation substrate in rats with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources